Dr Reddy's expands portfolio in Russia and CIS via in-licensing deals with Cipla and Vitabiotics
Hyderabad-based Dr Reddy’s Laboratories (DRL; NYSE: RDY), India’s second largest drugmaker, has entered into an agreement with fellow Indian firm Cipla (NSE: CIPLA; BSE 500087) for exclusive marketing rights to a portfolio of prescription drugs and over-the-counter medicines in the Russian and Ukraine markets.
Under the deal, financial terms of which were not disclosed, Dr Reddy’s has initiated the sales and promotion of the portfolio of products from second-quarter fiscal 2011 in select therapy areas in Russia. Launch in Ukraine will take place in the next calendar year.
The company has also entered into an agreement with UK based Vitabiotics for a range of nutraceutical products for Russia and select CIS countries. The accord provides Dr Reddy’s with exclusive marketing rights to two of Vitabiotics leading products - Jointace and Dietrim. Vitabiotics will supply these on a long term basis from its facilities in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze